FDA Determines Regulatory Review Period for ZILBRYSQ Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for ZILBRYSQ, a human drug product, in response to patent extension applications submitted to the US Patent and Trademark Office (USPTO).